NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.

B7-H1 Antigen / metabolism CD8-Positive T-Lymphocytes Histocompatibility Antigens Class I Humans NK Cell Lectin-Like Receptor Subfamily C / metabolism Programmed Cell Death 1 Receptor Urinary Bladder Neoplasms / therapy HLA-E Antigens
CD8 T cells HLA class I NK cells NKG2A bladder cancer checkpoint blockade immunotherapy immune exhaustion solid tumors tumor microenvironment

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
12 09 2022
Historique:
received: 16 12 2021
revised: 24 06 2022
accepted: 05 08 2022
entrez: 13 9 2022
pubmed: 14 9 2022
medline: 16 9 2022
Statut: ppublish

Résumé

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)-blockade immunotherapies have limited efficacy in the treatment of bladder cancer. Here, we show that NKG2A associates with improved survival and responsiveness to PD-L1 blockade immunotherapy in bladder tumors that have high abundance of CD8

Identifiants

DOI: 10.1016/j.ccell.2022.08.005 PMID: 36099881 PMC: PMC9479122
pubmed: 36099881
pii: S1535-6108(22)00369-5
doi: 10.1016/j.ccell.2022.08.005
pmc: PMC9479122
mid: NIHMS1830631
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
Histocompatibility Antigens Class I 0
KLRC1 protein, human 0
NK Cell Lectin-Like Receptor Subfamily C 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1043.e9

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI130760
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI164869
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA196521
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA078207
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201189
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests L.W., R.P.S., and J.Z. are employees of Sema4. A.H. receives research funds from Zumutor Biologics and is on the advisory boards of HTG Molecular Diagnostics, Immunorizon, UroGen, and Takeda. N.B. is an extramural member of the Parker Institute for Cancer Immunotherapy; receives research funds from Regeneron, Harbor Biomedical, DC Prime, and Dragonfly Therapeutics; and is on the advisory boards of Neon Therapeutics, Novartis, Avidea, Boehringer Ingelheim, Rome Therapeutics, Rubius Therapeutics, Roswell Park Comprehensive Cancer Center, BreakBio, Carisma Therapeutics, CureVac, Genotwin, BioNTech, Gilead Therapeutics, Tempest Therapeutics, and the Cancer Research Institute. A patent related to this work was filed to the United States Patent and Trademark Office (63/313,823).

Références

Cancer Lett. 2021 Feb 28;499:137-147
pubmed: 33249194
Eur J Immunol. 1999 Jan;29(1):23-9
pubmed: 9933082
J Clin Oncol. 2022 Oct 10;40(29):3383-3393
pubmed: 35452273
Sci Rep. 2017 May 23;7(1):2290
pubmed: 28536458
J Urol. 2015 Aug;194(2):556-62
pubmed: 25752441
BMC Bioinformatics. 2021 Mar 22;22(1):138
pubmed: 33752602
Science. 2018 Jan 5;359(6371):86-90
pubmed: 29302013
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:55-79
pubmed: 32421357
Immunity. 2022 Mar 8;55(3):512-526.e9
pubmed: 35263569
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Cell Rep. 2016 Jul 12;16(2):379-391
pubmed: 27373165
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Immunity. 1999 Jan;10(1):75-82
pubmed: 10023772
Nat Biotechnol. 2020 Dec;38(12):1408-1414
pubmed: 32747759
Nat Commun. 2020 Apr 20;11(1):1897
pubmed: 32312968
JAMA Oncol. 2019 Oct 01;5(10):1411-1420
pubmed: 31343665
Immunity. 2019 Dec 17;51(6):1043-1058.e4
pubmed: 31810882
PLoS One. 2014 Jun 11;9(6):e99432
pubmed: 24918932
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827905
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
Cancer Sci. 2021 May;112(5):1746-1757
pubmed: 33735485
Cancer. 2020 Sep 15;126(18):4156-4167
pubmed: 32673417
Cancer Res. 2013 Jan 15;73(2):617-28
pubmed: 23188505
Cancer Discov. 2016 Dec;6(12):1366-1381
pubmed: 27683557
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Eur J Immunol. 2005 Mar;35(3):766-75
pubmed: 15714583
J Exp Med. 1997 Feb 17;185(4):795-800
pubmed: 9034158
CA Cancer J Clin. 2020 Sep;70(5):404-423
pubmed: 32767764
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Int J Cancer. 2022 Feb 15;150(4):688-704
pubmed: 34716584
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
J Immunother Cancer. 2019 Oct 17;7(1):263
pubmed: 31623687
Eur J Immunol. 1997 Feb;27(2):563-7
pubmed: 9045931
J Exp Med. 1999 Sep 20;190(6):775-82
pubmed: 10499916
IEEE Int Symp Parallel Distrib Process Workshops Phd Forum. 2020 May;2020:183-192
pubmed: 33088611
JAMA Oncol. 2021 Jun 01;7(6):895-902
pubmed: 33792646
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Nat Commun. 2019 Jun 3;10(1):2387
pubmed: 31160572
Nat Methods. 2022 Feb;19(2):159-170
pubmed: 35027767
N Engl J Med. 2021 Jun 3;384(22):2102-2114
pubmed: 34077643
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
J Immunol. 1990 Apr 15;144(8):3238-47
pubmed: 1691231
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Sci Immunol. 2016 Sep;1(3):
pubmed: 27868107
FEBS J. 2016 Mar;283(5):947-61
pubmed: 26756195
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Clin Cancer Res. 2021 Aug 1;27(15):4287-4300
pubmed: 33837006
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
J Clin Invest. 2019 Apr 15;129(5):1839-1841
pubmed: 30985296
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Cell Rep. 2019 Jan 2;26(1):94-107.e7
pubmed: 30605689
Cancer. 2001 Sep 15;92(6):1475-83
pubmed: 11745225
J Immunol. 2020 Nov 15;205(10):2679-2693
pubmed: 33020148

Auteurs

Bérengère Salomé (B)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

John P Sfakianos (JP)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Daniel Ranti (D)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Jorge Daza (J)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Christine Bieber (C)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Andrew Charap (A)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Christian Hammer (C)

Department of Cancer Immunology, Genentech, South San Francisco, CA 94080, USA; Department of Human Genetics, Genentech, South San Francisco, CA 94080, USA.

Romain Banchereau (R)

Department of Oncology Biomarker Development, Genentech, South San Francisco, CA 94080, USA.

Adam M Farkas (AM)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Dan Fu Ruan (DF)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Sudeh Izadmehr (S)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Daniel Geanon (D)

Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Geoffrey Kelly (G)

Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Ronaldo M de Real (RM)

Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Brian Lee (B)

Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Kristin G Beaumont (KG)

Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Sanjana Shroff (S)

Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Yuanshuo A Wang (YA)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Ying-Chih Wang (YC)

Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Tin Htwe Thin (TH)

Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Monica Garcia-Barros (M)

Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Everardo Hegewisch-Solloa (E)

Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.

Emily M Mace (EM)

Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.

Li Wang (L)

Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Sema4, a Mount Sinai Venture, Stamford, CT 06902, USA.

Timothy O'Donnell (T)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Diego Chowell (D)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Ruben Fernandez-Rodriguez (R)

Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Mihaela Skobe (M)

Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Nicole Taylor (N)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Seunghee Kim-Schulze (S)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Robert P Sebra (RP)

Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Sema4, a Mount Sinai Venture, Stamford, CT 06902, USA; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Doug Palmer (D)

AstraZeneca, Oncology R & D Unit, Gaithersburg, MD 20878, USA.

Eleanor Clancy-Thompson (E)

AstraZeneca, Oncology R & D Unit, Gaithersburg, MD 20878, USA.

Scott Hammond (S)

AstraZeneca, Oncology R & D Unit, Gaithersburg, MD 20878, USA.

Alice O Kamphorst (AO)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Karl-Johan Malmberg (KJ)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

Emanuela Marcenaro (E)

Department of Experimental Medicine, University of Genoa, Genoa, Italy.

Pedro Romero (P)

Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.

Rachel Brody (R)

Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Mathias Viard (M)

Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.

Yuko Yuki (Y)

Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.

Maureen Martin (M)

Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.

Mary Carrington (M)

Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.

Reza Mehrazin (R)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Peter Wiklund (P)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Ira Mellman (I)

Department of Cancer Immunology, Genentech, South San Francisco, CA 94080, USA.

Sanjeev Mariathasan (S)

Department of Oncology Biomarker Development, Genentech, South San Francisco, CA 94080, USA.

Jun Zhu (J)

Center for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Sema4, a Mount Sinai Venture, Stamford, CT 06902, USA.

Matthew D Galsky (MD)

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Nina Bhardwaj (N)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: nina.bhardwaj@mssm.edu.

Amir Horowitz (A)

The Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: amir.horowitz@mssm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › NKG2A and HLA-E define an alternative immune...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › NKG2A and HLA-E define an alternative immune...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe I › NKG2A and HLA-E define an alternative immune...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › NKG2A and HLA-E define an alternative immune...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs de cellules tueuses naturelles › Récepteurs de cellules NK de type lectine › Sous-famille C des récepteurs de cellules NK de type lectine › NKG2A and HLA-E define an alternative immune...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › NKG2A and HLA-E define an alternative immune...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › NKG2A and HLA-E define an alternative immune...